Dara-CyBorD

Phase 2Small molecule

PPeking University People's Hospital

Dara-CyBorD is one of 25 small molecule programs targeting Dexamethasone. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DexamethasoneRecruiting

Monoclonal Gammopathy of Renal Significance (MGRS)Not yet recruiting

DexamethasonePhase 2

Recruiting

Monoclonal Gammopathy of Renal Significance (MGRS)Phase 2

Not yet recruiting

Competition

Competitive Landscape

31 competitors in Dexamethasone

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Rayos

3 3

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

16 4

Empliciti

Bristol-Myers Squibb

Phase 3

1 5

Velcade

SShilpa Grover, MD, MPH

Phase 3

8 6

Kyprolis

VVirionyx Corporation Limited

Phase 3

5 7

Zyprexa

MMODAG GmbH

Phase 3

3 8

Decadron

QQuince Therapeutics S.p.A.

Phase 3

2 9

Ninlaro

Takeda

Phase 2

3 10

Belamaf

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Dexamethasone

NCT06418477

Q4 2032

Phase 3Not yet recruiting

Light Chain (AL) Amyloidosis

NCT07709715

Clinical

Trials by Indication[1]

Dexamethasone1 trial

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

Recruiting·PPeking University People's Hospital·Phase 2·NCT06418477·20 enrolled

Light Chain (AL) Amyloidosis1 trial

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]

Not yet recruiting·NNexcella Inc.·Phase 3·NCT07709715·260 enrolled

Unspecified1 trial

Dara-BCD for Rare MGRS

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT06771180·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Dara-CyBorD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dara-CyBorD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dara-CyBorD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University People's Hospital

Dara-CyBorD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2032

Trials by Indication[1]

Dexamethasone1 trial

Light Chain (AL) Amyloidosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News